Welcome to our dedicated page for Precipio SEC filings (Ticker: PRPO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Precipio, Inc. (PRPO) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures, including current reports, quarterly reports, and other key documents filed with the U.S. Securities and Exchange Commission. As a NASDAQ-listed healthcare biotechnology company focused on cancer diagnostics, Precipio uses these filings to report on its financial performance, capital structure, and significant corporate events.
Investors can review Precipio’s periodic reports, such as its Quarterly Reports on Form 10-Q, which the company references in its earnings press releases. These filings contain detailed information on revenues from the pathology services and products divisions, gross margin trends, cash flow from operations, and non-GAAP measures such as EBITDA and Adjusted EBITDA, along with reconciliations to GAAP results. They also provide additional context on operating expenses, investments in laboratory and manufacturing capacity, and other factors influencing profitability.
Precipio’s current reports on Form 8-K highlight material events and investor communications. Recent 8-K filings have covered topics such as the termination of an at-the-market Sales Agreement with A.G.P./Alliance Global Partners, shareholder update calls, and the posting of an updated investor presentation. These filings often include press releases or presentation materials as exhibits, giving investors direct access to management’s commentary and strategic updates.
Through its filings, Precipio also discloses information about financing arrangements, warrant exercises, and debt obligations. For example, the company has reported on the termination of its ATM facility, the extent of shares sold under that agreement, and changes in its warrant structure. Press releases referenced in filings further describe the repayment of a Change Healthcare advance and the remaining small loan with the Connecticut Department of Economic and Community Development, providing insight into the company’s debt profile.
On Stock Titan, these SEC documents are supplemented by AI-powered tools that help interpret complex filings. Investors can use AI-generated summaries to understand the main points of lengthy 10-Q or 10-K reports, track Form 8-K events, and quickly identify disclosures related to revenue composition, margins, capital structure changes, and other topics relevant to a specialty cancer diagnostics company like Precipio.
Precipio, Inc. files its annual report describing an integrated cancer diagnostics business built around pathology services and proprietary products such as HemeScreen and IV-Cell. The company targets U.S. oncology labs and cites large addressable markets in oncology testing and diagnostic products.
For the year ended December 31, 2025, Precipio recorded an operating loss of $1.2 million, an accumulated deficit of $102.8 million, cash of $2.6 million and working capital of $2.3 million, leading auditors to express substantial doubt about its ability to continue as a going concern. One customer represented 26% of 2025 revenue, and government programs accounted for about 40% of revenue.
The company spent $1.6 million on research and development in 2025, continues to pursue patent protection for its technologies, and operates under complex U.S. and international regulatory regimes, including FDA, CLIA, EU IVDR, UKCA, HIPAA, GDPR and emerging state privacy laws. Management highlights liquidity needs, reimbursement risk, regulatory change, climate-related and macroeconomic pressures as key risk factors.
Precipio, Inc. reported preliminary, unaudited results showing a strong finish to 2025. Full-year 2025 revenues grew about 30% year-over-year. In Q4-2025, the company generated approximately $0.4 million in operating cash flow, reflecting a shift to cash-flow positivity.
Q4-2025 net income was about $0.5 million under GAAP, compared with a net loss of roughly $0.4 million in Q4-2024. Q4-2025 EBITDA was about $0.9 million, and Adjusted EBITDA was about $1.0 million, up from approximately $0.0 million and $0.4 million respectively in Q4-2024.
Management highlights becoming EBITDA- and cash-flow-positive as a key milestone that may allow greater focus on longer-term growth projects. More detailed discussion is expected on a shareholder call in early April, following the planned Form 10-K filing.
Leviticus Partners filed an amended Schedule 13G reporting beneficial ownership of 158,635 shares of Precipio, Inc. common stock, representing 9.1% of the class as of 12/31/2025.
The filer has sole voting and sole dispositive power over all reported shares and states the position is held in the ordinary course of business, not for the purpose of changing or influencing control of Precipio.
Precipio, Inc. director Ron A. Andrews reported acquiring 568 shares of common stock on 10/15/2025 at $17.58 per share. After this transaction, he beneficially owned 15,796 shares directly.
This is an amended Form 4 filed to correct his aggregate beneficial ownership, which the original filing understated by 88 shares because of an administrative reporting error. The amendment states that no additional transactions occurred beyond those already reported.
Precipio, Inc. director reports small share purchase and corrects prior filing
A director of Precipio, Inc. (PRPO) filed an amended Form 4 to update their reported holdings following a previously reported transaction. On 10/15/2025, the director acquired 746 shares of common stock at $17.58 per share. After this transaction, the director beneficially owned 53,688 shares of Precipio common stock.
The amendment explains that the director’s aggregate beneficial ownership in the original Form 4 filed on October 15, 2025 was understated by 116 shares due to an administrative reporting error, and that no additional transactions occurred beyond those already reported.
Precipio, Inc. director files amended Form 4 to correct share count. The filing shows a previously reported acquisition of 597 shares of common stock on 10/15/2025 at $17.58 per share, bringing the director’s reported beneficial ownership to 15,340 shares held directly.
The amendment explains that the director’s aggregate beneficial ownership in the original Form 4 filed on October 15, 2025 was understated by 93 shares due to an administrative reporting error. The note clarifies that no additional transactions took place beyond those already reported, and this correction only updates the total share balance.
Precipio, Inc. reported an updated insider transaction for its Chief Operating Officer on a Form 4/A. The filing shows the officer acquired 20 shares of common stock on 01/02/2026 at $23.40 per share under a Rule 10b5-1 trading plan, bringing the total beneficially owned amount to 1,015 shares of common stock held directly.
The amendment explains that a clerical error in the original Form 4 filed on January 2, 2026 understated the acquired shares as 735 instead of 1,015. No new transaction occurred; the amendment solely corrects the previously reported share count under the officer’s 10b5-1 plan.
Precipio, Inc. Chief Operating Officer Sabet Ahmed Zaki filed an amended insider trading report to correct a prior clerical error. The Form 4/A reflects an open‑market purchase of 25 shares of common stock at $19.50 per share, with 995 shares owned directly after the transaction. According to the footnote, the original filing understated the total holdings, reporting 715 instead of 995 shares, and this amendment only corrects that figure with no additional transaction beyond the original purchase under the reporting person's 10b5‑1 trading plan.
Precipio, Inc. Chief Operating Officer Sabet Ahmed Zaki reported an open-market purchase of 31 shares of common stock at $16.30 per share on July 8, 2025, increasing his direct holdings to 970 shares.
This Form 4/A is an amendment that corrects a clerical error in a prior Form 4 filed on November 20, 2025, where his post-transaction holdings were mistakenly shown as 690 shares. The amendment states that no additional transaction occurred and simply updates the recorded number of shares acquired under his Rule 10b5-1 trading plan.
Precipio, Inc. director Cohen David Seth received stock-based compensation for board service. On January 15, 2026, he was granted 546 shares of Precipio common stock at a stated price of $24 per share, issued as consideration instead of a cash payment for his compensation as a member of the Board of Directors for Q4-25. Following this grant, he beneficially owned 54,234 shares of Precipio common stock, held in direct ownership.